SecBot SecBot

NCEL

NewcelX Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. V8· CIK 0001783036 Biotech & Drug Discovery
$2.50 −0.16 (−6.02%)
Oct 26 4:00 PM ET · prev $2.66
Market cap
$14.8M
Nano cap
Median target
$23.00
+820% · range $23.00–23.00
1 year
−79.8%
from $12.40 · Oct 27
30 days
−14.4%
from $2.92
52-week range
$1.88–12.40
−80% from high · low Mar 30
Avg volume 20D
7.3K
Oct 16 spike 23.1K
Short interest
9.8K
≈0.2% of shares · −34.9%
Days to cover
1.6
at average volume
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 3 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/4
Strongest BEARISH NewcelX Ltd. filed its unaudited interim financial statements for H1 2026, reporting a net loss of $2.9M (vs…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersCOVERING

    Short interest −34.9% to 9.8K shares. 1.6 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F
Top holderSharesValue
HRT FINANCIAL LP11,199$40.0K
JONES FINANCIAL COMPANIES LLLP700$2.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +820%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 13, 2026Laidlaw & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$1.18-$1.18–-$1.18—$0.00
Next FY-$0.60-$0.60–-$0.60—$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 31, 2026
Press release
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND…
Jul 1, 2026
Press release
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX’s planned…
May 27, 2026
Announcement
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial
Apr 30, 2026
Earnings
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1…
Apr 20, 2026
Contract
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd . (Nasdaq: NCEL), a clinical-stage regenerative…

Short side

FINRA· Sep 30, 2026
9,777
shares short
-34.9%
vs prior settlement
1.6
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 SEC
The SEC declared effective NewcelX Ltd.'s registration statement on Form S-3 (File No. 333-290516) under the 1933 Act…
EFFECT — Impact 5/10
Sep 18, 2026 SEC
NewcelX Ltd. filed its unaudited interim financial statements for H1 2026, reporting a net loss of $2.9M (vs $11.3M in…
6-K — Impact 6/10
Aug 27, 2026 SEC
NewcelX Ltd. received SEC effectiveness on August 26, 2026 for its F-3 shelf registration (File No. 333-298458)…
EFFECT — Impact 5/10
Jul 31, 2026 Other
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabet
May 27, 2026 Press
NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy)…
Impact 5/10
Apr 20, 2026 Press
NewcelX announced an updated corporate presentation highlighting its strategic collaboration with Eledon…
Impact 5/10

SecBot reports

15 filings · 2 press releases · 3 bullish · 6 bearish · 1 mixed · 5 neutral
All NCEL filing & press-release reports (17)